Evidence map›Paper›PMID 42115606›Full record

ArticleNPJ Parkinson's disease2026

Shared and distinct lipid profiles in amygdala from sporadic and GBA-associated Parkinson's diseases.

Sonia S Muñoz, Frederik R Marlet, Jesper E Dreier, Mesut Bilgin, Katharina Schott, Krista B S Neergaard, Erwan Bezard, Benjamin Dehay, Zane Jaunmuktane, Kenji Maeda and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sonia S Muñoz *Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Frederik R Marlet *Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Jesper E DreierDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Mesut BilginLipidomics Core Facility, Danish Cancer Institute, Copenhagen, Denmark.
Katharina SchottDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Krista B S NeergaardDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Erwan BezardUniversity of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France.
Benjamin DehayUniversity of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France.
Zane JaunmuktaneDivision of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
Kenji MaedaCell Death and Metabolism Group, Center for Autophagy, Recycling and Disease, Danish Cancer Institute, Copenhagen, Denmark.
Céline GalvagnionDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. celine.galvagnion@sund.ku.dk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's Disease (PD) is a neurodegenerative disorder characterised by the deposition of protein-lipid inclusions, containing alpha-synuclein, neuronal cell loss and disruptions in lipid metabolism. GBA mutations are together an important genetic risk factor for PD and are associated with a decrease in glucocerebrosidase, a lysosomal glycoprotein encoded by GBA, an increase in alpha-synuclein and changes in the levels of glucocerebrosidase's substrates, glucosylsphingosine and glucosylceramide, and some sphingolipids. In this study, we found extensive metabolic remodelling of lipids, beyond glucocerebrosidase's substrates, in the amygdala from people with sPD and disease duration above 30 years (sPD

Identifiers

PMID42115606
PMCPMC13381535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.